In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.
A drug already used to treat people who have diabetes and/or chronic kidney disease could have added heart disease benefits, ...
Medscape News UK, February 27, 2025 Dual SGLT1/2 Inhibitor Protects Against MI and Stroke Sotagliflozin, a dual SGLT1/2 inhibitor, reduces cardiovascular events in people with diabetic kidney ...
The Role of Kidney in Glucose Homeostasis — SGLT2 Inhibitors, a New Approach in Diabetes Treatment
SGLT2 inhibitors are a new family of agents ... transporters located at the brush border of tubular cells (SGLT2 and SGLT1) and the GLUTs facilitated diffusion glucose transporters located ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback